Mitotane does not show a significant improvement in the relapse rate and is associated with adverse events in patients with adrenocortical carcinoma considered to be at low-to-intermediate risk for recurrence.
Low Recurrence Risk: No Mitotane for Adrenocortical Carcinoma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
After the complete tumor resection, not all patients with an adrenocortical carcinoma require the previous standard therapy Mitotane. Professors Martin Fassnacht and Massimo Terzolo show this in a clinical trial.
Study shows no mitotane needed for patients with low risk of recurrence of adrenocortical carcinoma medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
University of Turin, first graduates of the Medicine and Surgery course thenewsteller.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenewsteller.com Daily Mail and Mail on Sunday newspapers.
ASCO GU 2022: First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients: The ADIUVO Study urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.